机构名称：
¥ 1.0
•护理标准是1L宝石/顺式；没有1L治疗以外的护理标准； • First ICI approved for NPC (pembro and nivo approved in head & neck squamous cell carcinoma) • NCCN guidelines v4.2024 includes the following as preferred subsequent line option for recurrent, unresectable or metastatic disease (category 2A): Toripalimab (if disease progression on or after platinum-containing therapy) • NCCN Other Recommended Regimens includes subsequent line免疫疗法（2B级）：nivolumab，如果先前治疗，复发性或转移性非转化疾病阶段2（NCI-9742）n = 44; @13 MOS ORR 21％； 1年PFS 19％； 1 yr OS 59% 6 Pembrolizumab if previously treated, PD-L1+ recurrent or metastatic disease or TMB-High (> 10 mut/Mb) KEYNOTE-122 N=233 (pembro vs. chemo) Open-label, Phase 3 trial in PD-L1+ NPC @45 mos ORR 23 vs. 26%; OS 17 vs. 15 mos； [HR 0.90（95％CI 0.67-1.19）; p = 0.2262] 5
鼻咽癌中的toripalimab（loqtorzi）...
主要关键词
相关文件推荐
